OBJECTIVE： To observe the clinical efficacy and safety of different doses of atorvastatin in the treatment of chronic subdural hematoma （CSDH）. METHODS： One hundred and tweaty-eight CSDH patients selected from our hospital during Jun. 2013-May 2015 were divided into observation group （n＝62） and control group （n＝66） in accordance with random number table. Both groups were given conventional treatment of brain cell nutrition. Control group received Atorvastatin tablet 20 mg， po， qd； observation group received Atorvastatin tablet 40 mg， po， qd. Both groups were treated for 6 months. Clinical efficacy， CSS and ADL score， hematoma volume， the levels of serum inflammatory factors （hs-CRP， MMP-9， IL-6， TNF-α） were observed in 2 groups. ADR was recorded during treatment and recurrence rate was also recorded. RESULTS： Two patients withdrew from observation group and 6 from control group. Finally， 120 patients met the criteria were included， with 60 cases in each group. Total response rate of observation group （88.3％） was significantly better than that of control group （73.3％）， with statistical significance （P＜0.05）. After 1， 3， 6 months of treatment， CSS score， hematoma volume， the serum levels of hs-CRP， MMP-9， IL-6 and TNF-α in 2 groups were significantly decreased， while ADL score was increased significantly； the improvement of above indexes in observation group was significantly better than in control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. The recurrence rate of control group （13.3％） was significantly higher than that of observation group （3.3％）， with statistical significance （P＜0.05）.  CONCLUSIONS： Daily dose of shows atorvastatin 40 mg better therapeutic efficacy and lower recurrence rate in the treatment of CSDH with good safety.